Hospital Acquired Infections Therapeutic Market Size & Share Report, Growth, Trends, 2032
Hospital Acquired Infections Therapeutic Market By Drug Class (Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs), By Infection Type (Urinary Tract Infections, Ventilator-associated Pneumonia, Surgical Site Infections, Bloodstream Infections, Other Hospital Infections): Global Industry Perspective, Comprehensive Analysis and Forecast, 2020 - 2026
The global Hospital Acquired Infections Therapeutic Market size was USD 10.3 billion in 2023 and is expected to rise to USD 12.5 billion by 2032 at a CAGR of 2.4%.
Table Of Content
- Chapter 1.Preface
- 1.1.Report Description
- 1.1.Report Scope
- Chapter 2.Research Methodology
- 2.1.Research Methodology
- 2.2.Secondary Research
- 2.3.Primary Research
- 2.4.Models
- 2.4.1.Company Share Analysis Model
- 2.4.2.Revenue Based Modeling
- 2.5.Research Limitations
- Chapter 3.Executive Summary
- 3.1.Global Hospital Acquired Infections Therapeutic Market, 2016 – 2026 (Million)
- 3.2.Global Hospital Acquired Infections Therapeutic Market: Snapshot
- Chapter 4.Hospital Acquired Infections Therapeutic Market – Industry Analysis
- 4.1.Introduction
- 4.2.Market Drivers
- 4.3.Market Restraints
- 4.4.Market Opportunities
- 4.5.Porter’s Five Forces Analysis
- 4.6.COVID 19 Impact Analysis
- 4.6.1.1.Impact on Product Development and Technology Adoption
- 4.6.1.2.Gap Analysis
- Chapter 5.Investment Proposition Analysis
- 5.1.Global Hospital Acquired Infections Therapeutic Market Attractiveness, By Drug Class
- 5.2.Global Hospital Acquired Infections Therapeutic Market Attractiveness, By Infection Type
- 5.3.Global Hospital Acquired Infections Therapeutic Market Attractiveness, By Region
- Chapter 6.Competitive Landscape
- 6.1.Company Market Share Analysis - 2019
- 6.1.1.Global Hospital Acquired Infections Therapeutic Market: Company Market Share, 2019
- 6.2.Strategic Developments
- 7.1.Global Hospital Acquired Infections Therapeutic Market Overview: by Drug Class
- 7.1.1.Global Hospital Acquired Infections Therapeutic Market Revenue Share, by Drug Class, 2019 & 2026
- 7.2.Global Hospital Acquired Infections Therapeutic Market Analysis/Overview – By Drug Class
- 7.2.1.Antibacterial Drugs – Overview/Analysis
- 7.2.2.Antiviral Drugs – Overview/Analysis
- 7.2.3.Antifungal Drugs – Overview/Analysis
- 7.3.Antibacterial Drugs
- 7.3.1.Global Hospital Acquired Infections Therapeutic Market for Antibacterial Drugs, Revenue (Million) 2016 - 2026
- 7.4.Antiviral Drugs
- 7.4.1.Global Hospital Acquired Infections Therapeutic Market for Antiviral Drugs, Revenue (Million) 2016 - 2026
- 7.5.Antifungal Drugs
- 7.5.1.Global Hospital Acquired Infections Therapeutic Market for Antifungal Drugs, Revenue (Million) 2016 - 2026
- 8.1.Global Hospital Acquired Infections Therapeutic Market Overview: by Infection Type
- 8.1.1.Global Hospital Acquired Infections Therapeutic Market Revenue Share, by Infection Type, 2019 & 2026
- 8.2.Global Hospital Acquired Infections Therapeutic Market Analysis/Overview – By Infection Type
- 8.2.1.Urinary Tract Infections – Overview/Analysis
- 8.2.2.Ventilator-associated Pneumonia – Overview/Analysis
- 8.2.3.Surgical Site Infections – Overview/Analysis
- 8.2.4.Bloodstream Infections – Overview/Analysis
- 8.2.5.Other Hospital Infection – Overview/Analysis
- 8.3.Urinary Tract Infections
- 8.3.1.Global Hospital Acquired Infections Therapeutic Market for Urinary Tract Infections, Revenue (Million) 2016 - 2026
- 8.4.Ventilator-associated Pneumonia
- 8.4.1.Global Hospital Acquired Infections Therapeutic Market for Ventilator-associated Pneumonia, Revenue (Million) 2016 - 2026
- 8.5.Surgical Site Infections
- 8.5.1.Global Hospital Acquired Infections Therapeutic Market for Surgical Site Infections, Revenue (Million) 2016 - 2026
- 8.6.Bloodstream Infections
- 8.6.1.Global Hospital Acquired Infections Therapeutic Market for Bloodstream Infections, Revenue (Million) 2016 - 2026
- 8.7.Other Hospital Infection
- 8.7.1.Global Hospital Acquired Infections Therapeutic Market for Other Hospital Infection, Revenue (Million) 2016 - 2026
- 6.1.Company Market Share Analysis - 2019
- Chapter 9.Hospital Acquired Infections Therapeutic Market – Regional Analysis
- 9.1.Global Hospital Acquired Infections Therapeutic Market: Regional Overview
- 9.1.1.Global Hospital Acquired Infections Therapeutic Market Revenue Share, by Region, 2019 & 2026
- 9.1.2.Global Hospital Acquired Infections Therapeutic Market Revenue, by Region, 2016 – 2026 (Million)
- 9.2.North America
- 9.2.1.North America Hospital Acquired Infections Therapeutic Market Revenue, 2016 - 2026 (Million)
- 9.2.2.North America Hospital Acquired Infections Therapeutic Market Revenue, by Country, 2016 – 2026 (Million)
- 9.2.3.North America Hospital Acquired Infections Therapeutic Market Revenue, by Drug Class, 2016 – 2026
- 9.2.4.North America Hospital Acquired Infections Therapeutic Market Revenue, by Infection Type, 2016 – 2026
- 9.2.5. U.S.
- 9.2.6.Canada
- 9.3.Europe
- 9.3.1.Europe Hospital Acquired Infections Therapeutic Market Revenue, 2016 - 2026 (Million)
- 9.3.2.Europe Hospital Acquired Infections Therapeutic Market Revenue, by Country, 2016 – 2026 (Million)
- 9.3.3.Europe Hospital Acquired Infections Therapeutic Market Revenue, by Drug Class, 2016 – 2026
- 9.3.4.Europe Hospital Acquired Infections Therapeutic Market Revenue, by Infection Type, 2016 – 2026
- 9.3.5.Germany
- 9.3.6.France
- 9.3.7. U.K.
- 9.3.8.Italy
- 9.3.9.Spain
- 9.3.10.Rest of Europe
- 9.4.Asia Pacific
- 9.4.1.Asia Pacific Hospital Acquired Infections Therapeutic Market Revenue, 2016 - 2026 (Million)
- 9.4.2.Asia Pacific Hospital Acquired Infections Therapeutic Market Revenue, by Country, 2016 – 2026 (Million)
- 9.4.3.Asia Pacific Hospital Acquired Infections Therapeutic Market Revenue, by Drug Class, 2016 – 2026
- 9.4.4.Asia Pacific Hospital Acquired Infections Therapeutic Market Revenue, by Infection Type, 2016 – 2026
- 9.4.5.China
- 9.4.6.Japan
- 9.4.7.India
- 9.4.8.South Korea
- 9.4.9.South-East Asia
- 9.4.10.Rest of Asia Pacific
- 9.5.Latin America
- 9.5.1.Latin America Hospital Acquired Infections Therapeutic Market Revenue, 2016 - 2026 (Million)
- 9.5.2.Latin America Hospital Acquired Infections Therapeutic Market Revenue, by Country, 2016 – 2026 (Million)
- 9.5.3.Latin America Hospital Acquired Infections Therapeutic Market Revenue, by Drug Class, 2016 – 2026
- 9.5.4.Latin America Hospital Acquired Infections Therapeutic Market Revenue, by Infection Type, 2016 – 2026
- 9.5.5.Brazil
- 9.5.6.Mexico
- 9.5.7.Rest of Latin America
- 9.6.The Middle-East and Africa
- 9.6.1.The Middle-East and Africa Hospital Acquired Infections Therapeutic Market Revenue, 2016 - 2026 (Million)
- 9.6.2.The Middle-East and Africa Hospital Acquired Infections Therapeutic Market Revenue, by Country, 2016 – 2026 (Million)
- 9.6.3.The Middle-East and Africa Hospital Acquired Infections Therapeutic Market Revenue, by Drug Class, 2016 – 2026
- 9.6.4.The Middle-East and Africa Hospital Acquired Infections Therapeutic Market Revenue, by Infection Type, 2016 – 2026
- 9.6.5.GCC Countries
- 9.6.6.South Africa
- 9.6.7.Rest of Middle-East Africa
- 9.1.Global Hospital Acquired Infections Therapeutic Market: Regional Overview
- Chapter 10.Company Profiles
- 10.1.Merck & Co., Inc.
- 10.1.1.Company Overview
- 10.1.2.Financial Overview
- 10.1.3.Product Portfolio
- 10.1.4.Business Strategy
- 10.1.5.Recent Developments
- 10.2.Pfizer Inc.
- 10.3.Bayer AG
- 10.4.GlaxoSmithKline Plc.
- 10.5.Daiichi Sankyo Company, Limited
- 10.6.AbbVie Inc.
- 10.7.Abbott Laboratories
- 10.8.F. Hoffmann-La Roche Ltd
- 10.9.Allergan Plc.
- 10.1.Cubist Pharmaceuticals, Inc.,
- 10.1.Merck & Co., Inc.
Table Of Figures
List of Figures
FIG. 1 Research Methodology
FIG. 2 Research Methodology – Basic Overview
FIG. 3 Research Methodology – Detailed View
FIG. 4 Global Hospital Acquired Infections Therapeutic Market Revenue, 2016 - 2026 (Million)
FIG. 5 Porter’s Five Forces Analysis for Global Hospital Acquired Infections Therapeutic Market
FIG. 6 Global Hospital Acquired Infections Therapeutic Market Attractiveness, By Drug Class
FIG. 7 Global Hospital Acquired Infections Therapeutic Market Attractiveness, By Infection Type
FIG. 8 Global Hospital Acquired Infections Therapeutic Market Attractiveness, By End-User
FIG. 9 Company Share Analysis, 2019
FIG. 10 Global Hospital Acquired Infections Therapeutic Market Revenue Share, by Drug Class, 2019 & 2026
FIG. 11 Global Hospital Acquired Infections Therapeutic Market for Antibacterial Drugs, Revenue (Million) 2016 - 2026
FIG. 12 Global Hospital Acquired Infections Therapeutic Market for Antiviral Drugs, Revenue (Million) 2016 - 2026
FIG. 13 Global Hospital Acquired Infections Therapeutic Market for Antifungal Drugs, Revenue (Million) 2016 - 2026
FIG. 14 Global Hospital Acquired Infections Therapeutic Market Revenue Share, by Infection Type, 2019 & 2026
FIG. 15 Global Hospital Acquired Infections Therapeutic Market for Urinary Tract Infections, Revenue (Million) 2016 - 2026
FIG. 16 Global Hospital Acquired Infections Therapeutic Market for Ventilator-associated Pneumonia, Revenue (Million) 2016 - 2026
FIG. 17 Global Hospital Acquired Infections Therapeutic Market for Surgical Site Infections, Revenue (Million) 2016 - 2026
FIG. 18 Global Hospital Acquired Infections Therapeutic Market for Bloodstream Infections, Revenue (Million) 2016 - 2026
FIG. 19 Global Hospital Acquired Infections Therapeutic Market for Other Hospital Infection, Revenue (Million) 2016 - 2026
FIG. 20 Global Hospital Acquired Infections Therapeutic Market Revenue Share, by Region, 2019 & 2026
FIG. 21 North America Hospital Acquired Infections Therapeutic Market Revenue, 2016 - 2026 (Million)
FIG. 22 Europe Hospital Acquired Infections Therapeutic Market Revenue, 2016 - 2026 (Million)
FIG. 23 Asia Pacific Hospital Acquired Infections Therapeutic Market Revenue, 2016 - 2026 (Million)
FIG. 24 Latin America Hospital Acquired Infections Therapeutic Market Revenue, 2016 - 2026 (Million)
FIG. 25 The Middle-East and Africa Hospital Acquired Infections Therapeutic Market Revenue, 2016 - 2026 (Million)
Table Of Tables
List of Tables
TABLE 1 Global Hospital Acquired Infections Therapeutic Market: Snapshot
TABLE 2 Drivers of the Hospital Acquired Infections Therapeutic Market: Impact Analysis
TABLE 3 Restraints for the Hospital Acquired Infections Therapeutic Market: Impact Analysis
TABLE 4 Global Hospital Acquired Infections Therapeutic Market Revenue, by Region, 2016 – 2026 (Million)
TABLE 5 North America Hospital Acquired Infections Therapeutic Market Revenue, by Country, 2016 – 2026 (Million)
TABLE 6 North America Hospital Acquired Infections Therapeutic Market Revenue, by Drug Class, 2016 – 2026 (Million)
TABLE 7 North America Hospital Acquired Infections Therapeutic Market Revenue, by Infection Type, 2016 – 2026 (Million)
TABLE 8 Europe Hospital Acquired Infections Therapeutic Market Revenue, by Country, 2016 – 2026 (Million)
TABLE 9 Europe Hospital Acquired Infections Therapeutic Market Revenue, by Drug Class, 2016 – 2026 (Million)
TABLE 10 Europe Hospital Acquired Infections Therapeutic Market Revenue, by Infection Type, 2016 – 2026 (Million)
TABLE 11 Asia Pacific Hospital Acquired Infections Therapeutic Market Revenue, by Country, 2016 – 2026 (Million)
TABLE 12 Asia Pacific Hospital Acquired Infections Therapeutic Market Revenue, by Drug Class, 2016 – 2026 (Million)
TABLE 13 Asia Pacific Hospital Acquired Infections Therapeutic Market Revenue, by Infection Type, 2016 – 2026 (Million)
TABLE 14 Latin America Hospital Acquired Infections Therapeutic Market Revenue, by Country, 2016 – 2026 (Million)
TABLE 15 Latin America Hospital Acquired Infections Therapeutic Market Revenue, by Drug Class, 2016 – 2026 (Million)
TABLE 16 Latin America Hospital Acquired Infections Therapeutic Market Revenue, by Infection Type, 2016 – 2026 (Million)
TABLE 17 The Middle-East and Africa Hospital Acquired Infections Therapeutic Market Revenue, by Country, 2016 – 2026 (Million)
TABLE 18 The Middle-East and Africa Hospital Acquired Infections Therapeutic Market Revenue, by Drug Class, 2016 – 2026 (Million)
TABLE 19 The Middle-East and Africa Hospital Acquired Infections Therapeutic Market Revenue, by Infection Type, 2016 – 2026 (Million)
Methodology
FrequentlyAsked Questions
The Global Hospital Acquired Infections Therapeutic Market was valued at USD 10.3 billion in 2019.
The Global Hospital Acquired Infections Therapeutic Market is expected to reach USD 12.5 billion by 2026 at a CAGR of 2.4 % during the forecast period.
Some of the key factors driving the Global Hospital Acquired Infections Therapeutic Market growth are increase in number of hospital admitted patients , improved diagnostics capable of differentiating strains of microbes, the rising geriatric population, increase in R&D investments, etc.
. Europe dominated the market for Hospital Acquired Infections due to the high prevalence of HAIs in European countries and increasing approvals and launch of novel HAI therapeutic drugs in the region. Furthermore, higher accessibility of novel hospital-acquired infection therapeutics in the European is further expected to drive the growth of the region.
In Asia Pacific, the market for HAIs therapeutics is anticipated to show significant growth during the forecast period.
Who are the major companies operating in the Global Hospital Acquired Infections Therapeutic Market?
Some of the major companies operating in the Global Hospital Acquired Infections Therapeutic Market are Merck & Co., Inc., Pfizer Inc., Bayer AG, GlaxoSmithKline Plc., Daiichi Sankyo Company, Limited, AbbVie Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd., Cubist Pharmaceuticals, Inc., and Allergan Plc. among others.
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed